Fused pyrimidine derivatives as inhibitors of the KRAS oncoprotein

Pyridopyrimidine and pyrimido[4,5-d]pyrimidine compounds address the limitations of existing KRAS G12D inhibitors by enhancing selectivity and safety, effectively treating cancers through targeted inhibition of the KRAS oncoprotein.

JP2024545416AInactive Publication Date: 2024-12-06BETA PHARMA INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024532422
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-06-10
Filing Date
2022-11-29
Publication Date
2024-12-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current inhibitors for the Kirsten rat sarcoma virus (KRAS) oncoprotein, particularly targeting the G12D mutation, lack selectivity, safety, and efficacy in treating cancers such as lung, pancreatic, and colon cancers.

Method used

Development of pyridopyrimidine and pyrimido[4,5-d]pyrimidine compounds that act as inhibitors of the KRAS oncoprotein, specifically designed to target the G12D mutation, offering improved selectivity and safety profiles.

Benefits of technology

These compounds effectively inhibit KRAS G12D, providing therapeutic benefits for various cancers by reducing uncontrolled cell proliferation and cancer progression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024545416000001_ABST
    Figure 2024545416000001_ABST
Patent Text Reader

Abstract

The present invention is directed to certain pyridopyrimidine and pyrimido[4,5-d]pyrimidine inhibitors of the Kirsten rat sarcoma virus (KRAS) oncoprotein, more particularly represented by formula I The present invention is directed to compounds of formula I and compositions comprising the compounds of formula I, and methods of using the compounds of formula I for the treatment or prevention of diseases, disorders, or medical conditions mediated by KRAS, particularly the KRAS G12D oncoprotein.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application No. 63 / 284,067, filed November 30, 2021, and U.S. Provisional Application No. 63 / 350,987, filed June 10, 2022, both of which are incorporated by reference in their entireties. [Background technology]

[0002] TECHNICAL FIELD OF THEINVENTION The present invention is directed to inhibitors of Kirsten rat sarcoma virus (KRAS) oncoprotein, and more particularly to certain pyridopyrimidine and pyrimido[4,5-d]pyrimidine compounds, compositions, and methods for the treatment or prevention of diseases, disorders, or medical conditions mediated by KRAS, particularly the KRAS G12D oncoprotein, including various cancers.

[0003] Brief description of the related art Ras is a superfamily of small guanosine triphosphate (GTP)-binding proteins consisting of various isoforms. Ras genes can mutate into oncogenes that are associated with numerous cancers, including lung, pancreatic, and colon cancer. Ras is one of the most frequently mutated oncogenes. KRAS (Kirsten rat sarcoma virus), an isoform of Ras, is one of the most frequently mutated Ras genes, constituting approximately 86% of all known mutations. KRAS functions as an on / off switch in cell signaling. KRAS proteins are GTPases that act between inactive (GDP-bound) and active (GTP-bound) states to control various functions, including cell proliferation. However, mutated KRAS proteins cause uncontrolled cell proliferation and cancer. The KRAS-4B proteoform is the predominant isoform in colon (30-40%), lung (15-20%) and pancreatic cancers (90%) (Liu, P. et al., Acta Pharmaceutica Sinica B 2019, 9(5), 871-879). Thus, inhibitors of mutated KRAS proteins that bind GTP represent potential therapeutic agents for the treatment of various cancers.

[0004] Past attempts to design KRAS oncoprotein inhibitors have been largely unsuccessful, in large part due to the high affinity of KRAS oncoprotein for GTP. However, more recent approaches targeting KRAS G12C have shown promise. This mutation is present in approximately 50% of lung cancers and approximately 10-20% of all KRAS G12 mutations. The cysteine ​​residue of the mutation is positioned within the active site such that the sulfhydryl functional group can form a covalent bond with an appropriately functionalized binding ligand (Liu, Acta Pharmaceutica Sinica B 2019). This approach has identified irreversible covalent inhibitors of KRAS G12C that are currently in clinical trials. KRAS G12D mutations are found in approximately 4% of all non-small cell lung cancers, 13% of all colorectal cancers, 25% of pancreatic ductal adenocarcinomas, and 1.7% of small cell lung cancers (Cerami, E. and Sawyers, CL Cancer Discovery 2017, 7(8), 818-831). Given the prominent role of KRAS G12D as a driver of many malignancies, new KRAS G12D inhibitors with improved selectivity, safety, and efficacy are needed. Summary of the Invention

[0005] In one embodiment, the present invention provides a compound of formula I [ka] [During the ceremony, A is hydrogen, halogen, hydroxy, -C 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl, -C 0-3 Alkyl(C 3-6 Cycloalkyl), -C 1-6 Alkyl(halo), -C 1-6 Alkyl (OH), -O(C 1-4 alkyl), -C 1-3 Alkyl(C 1-4 Alkoxy), -CN, -COR 3 , -CO2N(R 3)2, -NO2, -N(R 3 )2, -P(O)(R 4 )2, -SR 3 , -S(O)R 3 , -SO2R 3 or aryl or heteroaryl optionally substituted with one or more 5- to 6-membered heterocyclic rings; W is CR 5 or N, provided that if W is N, then Y is CR 5 and; X is CR 5 or N, provided that if X is N, then Y is CR 5 and W is N; Y is CR 5 or N, with the proviso that if Y is N, then X and W are both CR 5 and; L is a bond, O, S, or NR 3 and; n is 0 to 2; Z is C 3-7 C(R) is selected from cycloalkyl, saturated or partially unsaturated 4- to 7-membered nitrogen-containing ring, and saturated or partially unsaturated 7- to 10-membered nitrogen-containing bridged bicyclic ring. 3 ) 2 or cyclic compounds; R 1 is hydrogen, hydroxy, halogen, -C 1-3 Alkyl, -C 1-3 Alkyl(OH), -C 1-3 Alkyl(halo), -C 1-3 Alkyl(C 1-3 Alkoxy), -C 1-3 Alkyl (CN) or -C 1-3 Alkyl (P(O)R 3 2) Selected from; R 2 is hydrogen, halogen, hydroxy, -C 1-4 Alkyl, -C 2-4 Alkenyl, -C 2-4 Alkynyl, -C 0-3 Alkyl(C 3-6 Cycloalkyl), -C 1-4 Alkyl(halo), -C 1-4Alkyl (OH), -O(C 1-4 alkyl), -C 1-3 Alkyl(C 1-3 Alkoxy), -CN, -COR 3 , -CO2N(R 3 )2, -NO2, -N(R 3 )2, -PO(R 4 )2, -SR 3 , -S(O)R 3 , -SO2R 3 , or -(C 0-3 Alkyl)R 6 Selected from; Each R 3 are the same or different, hydrogen, C 1-4 selected from alkyl, aryl, or heteroaryl; Each R 4 are the same or different and can be hydrogen, hydroxyl, C 1-4 Alkyl, aryl, heteroaryl, C 1-4 selected from alkoxy, aryloxy, or heteroaryloxy; Each R 5 may be the same or different, and are hydrogen, halogen, C 1-4 Alkyl, C 1-4 Perdeuteroalkyl, -(C 0-2 Alkyl)alkenyl, -(C 0-2 alkyl)alkynyl, -(C 0-2 alkyl)cycloalkyl, -C 1-4 Haloalkyl, -O(C 1-4 alkyl), -S(C 1-4 alkyl), -(C 0-2 alkyl)cyano, -O(C 1-4 haloalkyl) or -S(C 1-4 haloalkyl); R 6 is N(R 3 )2 or a 4- to 7-membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of N, O and S. or a pharma- ceutically acceptable salt, solvate, or prodrug thereof.

[0006] In another aspect, the present invention is directed to a pharmaceutical composition comprising a compound of formula I, or a salt, solvate, or prodrug thereof, in association with a pharma- ceutically acceptable carrier.

[0007] In another aspect, the present invention is directed to a method of treating a disease, disorder, or medical condition in a patient, comprising providing to a patient in need thereof a therapeutic agent comprising a compound of formula I, or a salt, solvate, or prodrug thereof.

[0008] These and other aspects may become evident from a reading of the following detailed description. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] Detailed Description of the Invention term Compounds are described using standard nomenclature. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0010] The use of "a" or "an" does not denote a limitation of quantity, but rather denotes the presence of at least one of the referenced item. The term "or" means "and / or." The terms "including" and "having" are intended to be open-ended terms (i.e., meaning "including, but not limited to").

[0011] Recitation of a range of values, unless otherwise stated herein, is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, and each separate value is incorporated herein as if each separate value were set forth individually herein. All range endpoints are included within the ranges and are independently combinable.

[0012] All methods described herein may be carried out in any suitable order unless otherwise indicated herein or clearly contradicted by the context. The use of any and all examples or illustrative expressions (e.g., "such as") is intended merely to better illustrate the invention and does not limit the scope of the invention unless otherwise claimed. No term in this specification should be construed as indicating any non-claimed element as essential to the practice of the invention used herein. Unless otherwise defined, technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art of this disclosure.

[0013] Furthermore, the disclosure encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms of one or more of the recited claims are introduced into another claim. For example, any claim that is dependent on another claim can be modified to include one or more limitations found in another claim that is dependent on the same base claim. When elements are presented as lists, for example in Markush group format, each subgroup of the elements is also disclosed, and any element can be removed from the group.

[0014] All compounds are understood to include all possible isotopes of the atoms present in the compound. Isotopes include atoms having the same atomic number but different mass numbers, and include heavy isotopes and radioisotopes. As common examples, isotopes of hydrogen include tritium and deuterium, and isotopes of carbon include 11 C. 13 C, and 14 These include, but are not limited to, C. Thus, the compounds disclosed herein may contain heavy or radioisotopes in the structure of the compound or as substituents attached thereto. Examples of useful heavy or radioisotopes include: 18 F, 15 N, 18 O. 76 Br, 125 I and 131 Contains I.

[0015] Every formula disclosed herein includes all salts of that formula.

[0016] The open-ended term "comprising" includes the intermediate and closed terms "consisting essentially of" and "consisting of."

[0017] The term "substituted" means that any one or more hydrogens on the specified atom or group are replaced with a selection from the indicated group, provided that the normal valence of the specified atom is not exceeded. Combinations of substituents and / or variables are permissible only if the combination results in a stable compound or useful synthetic intermediate. A stable compound or stable structure is intended to imply a compound that has sufficient robustness to survive isolation from a reaction mixture, and subsequent formulation into an effective therapeutic agent.

[0018] A dash ("-") that is not between two letters or symbols is used to indicate a point of attachment for a substituent.

[0019] "Alkyl" includes both branched and straight-chain saturated aliphatic hydrocarbon groups having a specified number of carbon atoms, typically from 1 to about 8 carbon atoms. 1-6 The terms alkyl, C1-C6 alkyl and C1-C6 alkyl all refer to alkyl groups having 1, 2, 3, 4, 5, or 6 carbon atoms. Other embodiments include alkyl groups having 1-8 carbon atoms, 1-4 carbon atoms, or 1 or 2 carbon atoms, such as C 1-8 Alkyl, C 1-4 Alkyl, and C 1-2 As used herein, C 0-n When alkyl is used with other groups, e.g., -C 0-4In alkyl(phenyl), the indicated group, in this case phenyl, is either directly attached by a single covalent bond (CO alkyl) or by an alkyl chain having the specified number of carbon atoms, in this case 1, 2, 3 or 4 carbon atoms. Alkyl is represented by -OC 0-4 Alkyl(C 3-7 As in cycloalkyl, it may also be attached via other groups such as a heteroatom. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, 3-methylbutyl, t-butyl, n-pentyl, and sec-pentyl.

[0020] "Alkoxy" refers to an alkyl group as defined above with the indicated number of carbon atoms covalently bonded to a substituent through an oxygen bridge (-O-). Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, 2-butoxy, t-butoxy, n-pentoxy, 2-pentoxy, 3-pentoxy, isopentoxy, neopentoxy, n-hexoxy, 2-hexoxy, 3-hexoxy, and 3-methylpentoxy. Similarly, an "alkylthio" or "thioalkyl" group refers to an alkyl group as defined above with the indicated number of carbon atoms covalently bonded to a substituent through a sulfur bridge (-S-). Similarly, "alkenyloxy", "alkynyloxy", and "cycloalkyloxy" refer to alkenyl, alkynyl, and cycloalkyl groups, in each instance, covalently bonded to a substituent through an oxygen bridge (-O-).

[0021] "Halo" or "halogen" means fluoro, chloro, bromo, or iodo, and is defined herein to include all isotopes thereof, including heavy and radioisotopes. Examples of useful halo isotopes include: 18 F, 76 Br, and 131 I. Additional isotopes will be readily apparent to those of ordinary skill in the art.

[0022] "Haloalkyl" refers to both branched and straight chain alkyl groups having the specified number of carbon atoms and substituted with one or more halogen atoms, generally up to the maximum number of halogen atoms permitted. Examples of haloalkyl include, but are not limited to, trifluoromethyl, difluoromethyl, 2-fluoroethyl, and penta-fluoroethyl.

[0023] "Haloalkoxy" is a haloalkyl group as described above attached through an oxygen bridge (the oxygen of an alcohol radical).

[0024] "Peptide" means a molecule that is a chain of amino acids linked through amide bonds (also called peptide bonds).

[0025] "Pharmaceutical composition" means a composition that contains at least one active agent, such as a compound or salt of Formula I, and at least one other substance, such as a carrier. The pharmaceutical composition meets U.S. FDA Good Manufacturing Practice (GMP) standards for human or non-human pharmaceuticals.

[0026] "Carrier" refers to a diluent, excipient, or vehicle with which an active compound is administered. "Pharmaceutically acceptable carrier" refers to a substance, e.g., an excipient, diluent, or vehicle, that is generally safe, non-toxic, and not biologically or otherwise undesirable, useful in preparing pharmaceutical compositions, including carriers that are acceptable for veterinary and human pharmaceutical use. "Pharmaceutically acceptable carrier" includes both one such carrier and more than one such carrier.

[0027] "Patient" means a human or non-human animal in need of medical treatment. Medical treatment can include treatment of an existing condition, such as a disease or disorder, or a diagnostic treatment. In some embodiments, the patient is a human patient.

[0028] "Providing" means giving, administering, selling, distributing, transferring (whether or not for profit), manufacturing, compounding, or distributing.

[0029] "Treatment" or "treating" refers to providing a patient with a sufficient amount of an active compound to measurably reduce any disease symptoms, slow the progression of the disease, or cause regression of the disease. In certain embodiments, treatment of a disease can begin before the patient exhibits symptoms of the disease.

[0030] A "therapeutically effective amount" of a pharmaceutical composition means an amount effective, when administered to a patient, to provide a therapeutic benefit, such as amelioration of symptoms, reduction in the progression of a disease, or regression of a disease.

[0031] "Therapeutic compound" means a compound that can be used in the diagnosis or treatment of a disease. The compound can be a small molecule, a peptide, a protein, or other type of molecule.

[0032] A significant change is any detectable change that is statistically significant in a standard parametric test of statistical significance, such as Student's T-test, where p<0.05.

[0033] chemical description Compounds of the formula disclosed herein may contain one or more asymmetric elements, such as stereogenic centers (e.g., asymmetric carbon atoms), stereogenic axes, rotationally hindered rotamers (e.g., atropisomers), so that the compounds may exist in different stereoisomeric forms. For compounds with two or more asymmetric elements, these compounds may further be mixtures of diastereomers. For compounds with asymmetric centers, all optical isomers in pure form and mixtures thereof are included. For compounds with asymmetric centers, all optical isomers in pure form and mixtures thereof are included. In these situations, single enantiomers, i.e., optically active forms, can be obtained by asymmetric synthesis, synthesis from optically pure precursors, or separation of the racemates. Separation of the racemates can also be achieved by conventional methods, such as, for example, crystallization in the presence of a resolving agent, or chromatography, for example, using a chiral HPLC column. All forms are contemplated herein, regardless of the method used to obtain them.

[0034] All forms of the compounds of the present invention (eg, solvates, optical isomers, enantiomeric forms, polymorphs, prodrugs, free base compounds and salts) may be used alone or in combination.

[0035] The term "chiral" refers to a molecule having the property of non-superimposability on its mirror image partner.

[0036] "Stereoisomers" are compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.

[0037] The term "solvate" refers to a chemical complex formed by the interaction of a solvent and a solute, such as a compound of the invention.

[0038] The term "prodrug" refers to a biologically inactive compound that can be metabolized inside or outside the body to yield a drug.

[0039] "Diastereomers" are stereoisomers that have two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g., melting points, boiling points, spectral properties, and reactivities. Mixtures of diastereomers can be separated by high resolution analytical procedures such as electrophoresis, crystallization in the presence of a resolving agent, or chromatography, e.g., using a chiral HPLC column.

[0040] "Enantiomers" refers to two stereoisomers of a compound that are non-superimposable mirror images of one another. A 50:50 mixture of enantiomers is called a racemic mixture or racemate, and may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process.

[0041] The stereochemical definitions and conventions used herein are generally those of SP Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., Stereochemistry of Organic Compounds (1994) John Wiley & Sons, Inc., New York. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. In describing optically active compounds, the prefixes D and L, or R and S, are used to indicate the absolute configuration of the molecule about its chiral center. The prefixes d and l, or (+) and (-), are used to indicate the sign of rotation of plane-polarized light by the compound, with (-) or l meaning that the compound is levorotatory. Compounds with a (+) or d prefix are dextrorotatory.

[0042] A "racemic mixture" or "racemate" is an equimolar (or 50:50) mixture of two enantiomeric species, devoid of optical activity. A racemic mixture may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process.

[0043] A "chelating group" or "chelator" is a ligand group capable of forming two or more separate coordinate bonds to a single central atom, usually a metal ion. The chelating groups disclosed herein are organic groups having multiple N, O, or S heteroatoms and a structure in which the two or more heteroatoms can form bonds to the same metal ion.

[0044] "Salt" includes derivatives of the disclosed compounds modified by making the parent compound into its inorganic and organic salts, acid addition salts or base addition salts. The salts of the compounds of the present invention can be synthesized from the parent compound containing a basic or acidic moiety by conventional chemical methods. In general, such salts can be prepared by reacting the free acid forms of these compounds with a stoichiometric amount of a suitable base (such as hydroxides, carbonates, bicarbonates of Na, Ca, Mg, or K) or by reacting the free base forms of these compounds with a stoichiometric amount of a suitable acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of both. Generally, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are used wherever practicable. The salts of the compounds of the present invention further include solvates of the compounds of the present invention and salts of the compounds of the present invention. In some embodiments, the compounds of the present invention are synthesized or isolated as trifluoroacetic acid (TFA) salts.

[0045] In some embodiments, the salt form of the compound of the present invention above can include pharmaceutically acceptable salt.The examples of pharmaceutically acceptable salt include but are not limited to non-toxic mineral or organic acid salts of basic residues such as amines; alkali salts or organic acid salts of acidic residues such as carboxylic acids; and the like.Pharmaceutically acceptable salts include conventional salts and, for example, the quaternary ammonium salts of parent compounds formed from non-toxic inorganic or organic acids. For example, conventional non-toxic acid salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid, and nitric acid; and acid salts of acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, pamoic acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, mesylic acid, esylic acid, besylic acid, sulfanilic acid, 2-acetoxybenzoic acid, fumaric acid, toluenesulfonic acid, methanesulfonic acid, ethanedisulfonic acid, oxalic acid, isethionic acid, and HOOC-(CH2). n and salts prepared from organic acids such as -COOH, where n is 0 to 4. Further lists of suitable salts can be found, for example, in G. Steffen Paulekuhn, et al., Journal of Medicinal Chemistry 2007, 50, 6665 and Handbook of Pharmaceutically Acceptable Salts: Properties, Selection and Use, P. Heinrich Stahl and Camille G. Wermuth, Editors, Wiley-VCH, 2002.

[0046] In a preferred embodiment, the compound of formula I is represented by structures 1-aa through 1-gd and 2-aa through 2-gc, as shown below, including pharma- ceutically acceptable salts, solvates, or prodrugs thereof: [ka] [ka]

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

[0047] Particularly preferred compounds are 1-ap, 1-bo, 1-ca, 1-dk, 1-ei, 1-gb, 2-ab, 2-af, 2-ba, 2-be, 2-ca, 2-ce, 2-da, 2-de, 2-ea, 2-ee, and 2-fa: [ka] [ka]

[0048] The compounds disclosed herein may be administered to a patient as neat or free base chemicals, but are preferably administered as pharmaceutical compositions. Thus, the present invention encompasses pharmaceutical compositions comprising a compound, such as a compound of formula I, or a salt of the compound (including a pharma- ceutically acceptable salt), together with at least one pharma- ceutically acceptable carrier. The pharmaceutical composition may comprise a compound or salt of formula I as the only active agent, but preferably comprises at least one additional active agent. In certain embodiments, the pharmaceutical composition is a dosage form comprising about 0.1 mg to about 2000 mg, about 10 mg to about 1000 mg, about 100 mg to about 800 mg, or about 200 mg to about 600 mg of a compound of formula I in a unit dosage form, and optionally about 0.1 mg to about 2000 mg, about 10 mg to about 1000 mg, about 100 mg to about 800 mg, or about 200 mg to about 600 mg of an additional active agent in a unit dosage form. For example, the pharmaceutical composition may include about 0.5:1, about 1:1, about 2:1, about 3:1, or about 1.5:1 to about 4:1 molar ratio of the additional active agent to the compound of formula I. Particularly preferred forms of the compound of formula I for use in pharmaceutical compositions include compounds 1-ap, 1-bo, 1-ca, 1-dk, 1-ei, 1-gb, 2-ab, 2-af, 2-ba, 2-be, 2-ca, 2-ce, 2-da, 2-de, 2-ea, 2-ee, and 2-fa, or salts, solvates or prodrugs thereof, in association with a pharma- ceutically acceptable carrier.

[0049] The compounds disclosed herein can be administered orally, topically, parenterally, by inhalation or spray, sublingually, transdermally, via buccal administration, rectally, as eye drops, or by other means in dosage unit formulations containing conventional pharma- ceutically acceptable carriers. Pharmaceutical compositions can be formulated in any pharma- ceutically useful form, for example, aerosols, creams, gels, pills, capsules, tablets, syrups, transdermal patches, or eye drops. Some dosage forms, for example, tablets and capsules, are subdivided into unit doses of suitable size, containing an appropriate amount of active ingredient, for example, an effective amount to achieve the desired purpose.

[0050] Carriers include excipients and diluents and must be of sufficiently high purity and sufficiently low toxicity to be suitable for administration to the patient being treated.Carriers may be inert and may have pharmaceutical benefits of their own.The amount of carrier used with the compound is sufficient to provide a practical amount of material for administration per unit dose of the compound.

[0051] Types of carriers include, but are not limited to, binders, buffers, colorants, diluents, disintegrants, emulsifiers, flavorings, glidants, lubricants, preservatives, stabilizers, surfactants, tableting agents, and wetting agents. Some carriers may be listed in more than one category, for example, vegetable oils may be used as lubricants in some formulations and as diluents in others. Exemplary pharma- ceutical acceptable carriers include sugar, starch, cellulose, powdered tragacanth, malt, gelatin, talc, and vegetable oils. The pharmaceutical composition may include any active agent that does not substantially inhibit the activity of the compound of the present invention.

[0052] The pharmaceutical compositions / combinations can be formulated for oral administration. These compositions contain 0.1-99% by weight (wt%) of the compound of formula I, and usually contain at least about 5 wt% of the compound of formula I. Some embodiments contain about 25 wt% to about 50 wt% or about 5 wt% to about 75 wt% of the compound of formula I.

[0053] Treatment The compounds of formula I and pharmaceutical compositions comprising said compounds are useful for the diagnosis or treatment of diseases, disorders, or medical conditions mediated by KRAS, particularly the KRAS mutant G12D, including various cancers such as glioma (glioblastoma), acute myelogenous leukemia, acute myeloid leukemia, myelodysplastic / myeloproliferative neoplasms, sarcoma, chronic myelomonocytic leukemia, non-Hodgkin's lymphoma, astrocytoma, melanoma, non-small cell lung cancer, small cell lung cancer, cholangiocarcinoma, chondrosarcoma, colon cancer, colorectal cancer, rectal cancer, pancreatic cancer, and combinations thereof.

[0054] According to the present invention, the method for treating KRAS-mediated disease or condition comprises providing the patient who needs such treatment with a therapeutically effective amount of the compound of formula I. In some embodiments, the patient is a mammal, more specifically, a human.As will be understood by those skilled in the art, the present invention also encompasses the method for treating non-human patients, such as pets, for example, cats, dogs, and livestock.

[0055] The therapeutically effective amount of the pharmaceutical composition is preferably an amount sufficient to reduce or improve the symptoms of a disease or condition.In the case of a disease mediated by KRAS, for example, the therapeutically effective amount may be an amount sufficient to reduce or improve cancer.The therapeutically effective amount of the compound or pharmaceutical composition described herein also provides a sufficient concentration of the compound of formula I when administered to a patient.The sufficient concentration is preferably the concentration of the compound in the patient's body that is necessary to prevent or combat the disorder.Such an amount can be confirmed experimentally, for example, by measuring the blood concentration of the compound, or theoretically, by calculating bioavailability.

[0056] According to the present invention, the treatment method disclosed herein comprises providing a patient with a specific dosage of the compound of formula I. Dosage levels of about 0.1 mg to about 140 mg of each compound per kg of body weight per day are useful in the treatment of the above conditions (about 0.5 mg to about 7 g per patient per day). The amount of compound that can be combined with a carrier material to produce a single dosage form varies depending on the patient being treated and the particular mode of administration. Dosage unit forms generally contain about 1 mg to about 500 mg of each active compound. In certain embodiments, 25 mg to 500 mg, or 25 mg to 200 mg of the compound of formula I are provided to the patient daily. The frequency of administration can also vary depending on the compound used and the particular disease being treated. However, for the treatment of most KRAS-mediated diseases and disorders, a dosing regimen of four times per day or less can be used, and in certain embodiments, a dosing regimen of once or twice per day is used.

[0057] However, it will be understood that the specific dose level for any particular patient will depend on a variety of factors, including the activity of the particular compound used, age, body weight, general health, sex, dietary habits, time of administration, route of administration and excretion rate, drug combination, and the severity of the particular disease being treated.

[0058] The compound of formula I can be administered alone (i.e., the only therapeutic agent in the regimen) or in combination with another active agent to treat or prevent KRAS-mediated diseases and conditions, such as various cancers. The form of formula I can be used in combination with or without another active agent. For example, in some embodiments, one, two, three, four or more compounds of formula I can form a therapeutic combination with or without additional active agents. One or more compounds of formula I can be administered in concert with a regimen of one or more other active agents, such as anti-cancer cytotoxic agents. In some embodiments, the method of treating or diagnosing KRAS-mediated cancer in a mammal comprises administering to said mammal a therapeutically effective amount of a compound of formula I, optionally in combination with one or more additional active ingredients.

[0059] As will be appreciated by those of skill in the art, the methods of treatment provided herein are also useful for treating mammals other than humans, including veterinary applications, such as for treating horses and livestock, e.g., cattle, sheep, cows, goats, pigs, etc., as well as companion animals, such as dogs and cats.

[0060] For diagnostic or research applications, a wide variety of mammals are suitable subjects, including rodents (e.g., mice, rats, hamsters), rabbits, primates, and pigs, such as inbred pigs. Additionally, for in vitro applications, such as in vitro diagnostic and research applications, bodily fluids (e.g., blood, plasma, serum, interstitial fluid, saliva, feces, and urine) and cell and tissue samples from the subjects are suitable for use.

[0061] In certain embodiments, the present invention provides a method of treating a disease, disorder, or medical condition mediated by KRAS, particularly KRAS mutant G12D, including various cancers, in a patient identified as in need of such treatment, the method comprising providing to the patient an effective amount of a compound of formula I. The compounds of formula I provided herein can be administered alone or in combination with one or more other active agents.

[0062] In another embodiment, the method of treating or diagnosing a KRAS-mediated disease or condition may further comprise administering to a patient in need of such treatment a compound of formula I in combination with one or more additional compounds, wherein the additional compounds are active agents. The one or more additional compounds may be doxorubicin, paclitaxel, docetaxel, cisplatin, camptothecin, temozolomide, avastin, herceptin, erbitux, EGFR inhibitors, osimertinib, rezivertinib, CDK4 / 6 inhibitors, abemaciclib, palbociclib, ribociclib, c-MET inhibitors, capmatinib, volitinib, ALK inhibitors, crizotinib, In some embodiments, the therapeutic agent may include additional therapeutic compounds, including anti-cancer cytotoxic agents and / or anti-cancer therapeutic compounds, such as rifabutinib, alectinib, ceritinib, brigatinib, entrectinib, lorlatinib, PD-1 antagonists, PD-L1 antagonists, ipilimumab, embrolizumab, and nivolumab, and combinations thereof. EXAMPLES

[0063] chemical synthesis The compounds of formula I described herein, and / or pharma- ceutically acceptable salts thereof, can be synthesized from commercially available starting materials by methods well known to those skilled in the art of organic synthetic chemistry. The following general synthetic schemes 1-4 show representative methods for preparing most of the exemplary compounds. In certain instances where the Suzuki cross-coupling reaction of arylboronic acids / esters with organic halides / pseudohalides (Beketskaya, IP et al., Coordin. Chem. Rev. 2019, 385, 137-173) is impractical or unsuccessful, the corresponding Stille cross-coupling reaction of organostannanes with organic halides / pseudohalides can be used as an alternative (Espinet, P. et al., ACS Catal. 2015, 5, 3040-3053). The starting materials, reactions, reagents, solvents, temperatures, catalysts and ligands described are not limited to those depicted purely for illustrative purposes. Certain abbreviations and acronyms that may be used in Schemes 1-7 and the Examples, which are well known to those of skill in the art, are set forth below for clarity.

[0064] In scheme 1, W is nitrogen and Y and X are both CR 5 and L is O, S or NR 3The synthesis of pyrido[2,3-d]pyrimidine examples 1a-c of formula I is shown, which are either: 1a, 2b, 3c, 3d, 3d, 3ds ... The base may be selected from K2CO3, Cs2CO3, DIEA or potassium t-butoxide, potassium bis(trimethylsilyl)amide or sodium hydride. Depending on the base, the appropriate solvent may be selected from THF, 1,4-dioxane, acetonitrile, DMA, NMP and alcohols. In the particular case (1j) where L is O, another palladium-mediated coupling reaction with 1i can be used to obtain compound 1m. Typical conditions for this coupling reaction are PdCl2, DTBPF, and K2CO3 in a mixture of 1,4-dioxane and water at elevated temperature. Subsequent Suzuki coupling of compounds 1m-1o with either boronic acid 1p or the corresponding boronic acid ester in the presence of Pd(dppf)Cl2 and KOAc gives the corresponding coupling products 1q-1s. Removal of the Boc group from compounds 1q-1s under acidic conditions, such as a mixture of TFA in DCM, gives the desired products 1a-1c. [ka]

[0065] In scheme 2, W and X are both nitrogen and Y is CR 5 and L is O, S or NR 3The synthesis of pyrimido[4,5-d]pyrimidine examples 2a-c of formula I is shown, which are either: 1) Suzuki coupling of compound 2d with either boronic acid 1p or the corresponding borate ester in the presence of Pd(OAc)2, DTBPF, and K3PO4 gives the corresponding coupling product 2e. Reaction of 2e with methyl chloroformate in the presence of sodium hydride gives the carbamate 2f. Dropwise addition of 30% H2O2 to a solution of 2f in the presence of sodium hydroxide gives compound 2g. Chlorination of 2g with phosphorus oxychloride in the presence of Hunig's base gives compound 2h. Subsequent reaction of 2h with 3,8-diazabicyclo[3.2.1]octane derivative 1h followed by treatment with (Boc)2O gives intermediate 2i. Treatment of compounds 1j-1l with base in a suitable solvent followed by reaction with intermediate 2i gives the corresponding compounds 2j-2l. The base can be selected from K2CO3, Cs2CO3, DIEA or potassium t-butoxide, potassium bis(trimethylsilyl)amide or sodium hydride. Depending on the base, the appropriate solvent can be selected from THF, 1,4-dioxane, acetonitrile, DMA, NMP and alcohols. In the particular case (1j) where L is O, another palladium-mediated coupling reaction with 2i can be used to obtain compound 2j. Typical conditions for this coupling reaction are PdCl2, DTBPF, and K2CO3 in a mixture of 1,4-dioxane and water at elevated temperature. Removal of the Boc group from compounds 2j-2l under acidic conditions, such as a mixture of TFA in DCM, gives the desired products 2a-2c. [ka]

[0066] In scheme 3, Y is nitrogen and W and X are both CR 5 and L is O, S or NR 3The synthesis of pyrido[2,3-d]pyrimidine examples 3a-c of formula I is shown, which are either of the following: 3-aminopicolinic acid 3d is reacted with urea in the presence of 0.2 M aqueous sodium hydroxide to give pyrido[3,2-d]pyrimidine-2,4(1H,3H)-dione 3e. 3e is chlorinated with a mixture of POCl3 and PCl5 to give the corresponding trichlorinated product 3f. 3f is then reacted with 3,8-diazabicyclo[3.2.1]octane derivative 1h, followed by treatment with (Boc)2O to give intermediate 3g. Compounds 1j-k are treated with a base in a suitable solvent, followed by reaction with intermediate 3g to give the corresponding compounds 3h-3j. The base may be selected from K2CO3, Cs2CO3, DIEA, or potassium t-butoxide, potassium bis(trimethylsilyl)amide, or sodium hydride. Depending on the base, suitable solvents can be selected from THF, 1,4-dioxane, acetonitrile, DMA, NMP, and alcohols. Alternatively, 1i-1k and 3g can be coupled with Pd(OAc)2 in the presence of BINAP and Cs2CO3 in toluene at elevated temperature to produce compounds 3h-3j. Subsequent Suzuki coupling of compounds 3h-3j with either boronic acid 1p or the corresponding boronic acid ester in the presence of Pd(dppf)Cl2 and KOAc gives the corresponding coupling products 3k-3m. Alternative conditions for this Suzuki coupling reaction are PdCl2, DTBPF, and K2CO3 in a mixed solvent of 1,4-dioxane and water at elevated temperature. Removal of the Boc group from compounds 3k-3m under acidic conditions such as HCl in 1,4-dioxane or TFA in dichloromethane gives the desired products 3a-3c. [ka]

[0067] Scheme 4 shows the synthesis of an example of formula I represented by 4 where L is methylene. Reaction of the terminal acetylene 4b with a strong base such as sodium hydride produces the corresponding acetylide anion, which can be reacted with compound 4a to give 4c. Alternatively, Sonogashira coupling of 4b with 4b using a Pd catalyst such as Pd(dppf)2Cl2 can give compound 4c (Plenio, H. and Schulz, MJ Org. Chem. 2012, 77(6), 2798-2807). Suzuki coupling of 4c with 1p under standard conditions followed by catalytic hydrogenation gives 4d. Removal of the Boc group under acidic conditions such as TFA in dichloromethane gives the desired amine product 4. [ka]

[0068] Scheme 5 shows the R 7 or R 8 is fluorine and L is O, S or NR 3The synthesis of compounds 5a and 5b of formula I, which are either: 5a, 5b, 5c, 5d, 5e, 5f, 5g, 5h ... Treatment with a base such as sodium hydride, Hunig's base, K2CO3 or Cs2CO3 / DABCO mixture followed by reaction with either 5g or 5h in a polar aprotic solvent such as N-methyl-2-pyrrolidone at room temperature or elevated temperature gives compounds 5i and 5j, respectively. Alternatively, 5g or 5h and 1i-k can be coupled with Pd(OAc)2 in the presence of BINAP and Cs2CO3 in toluene at elevated temperature to give 5i and 5j. Reaction of either 5i or 5j with a fluoride source such as potassium fluoride or cesium fluoride in a polar aprotic solvent such as DMSO at elevated temperature gives the corresponding fluorine products 5k and 5l. Compounds 5m and 5n can be prepared using standard Suzuki coupling procedures with either compound 5k or 5l and 1p in a solvent mixture such as 1,4-dioxane and water, respectively. Removal of the Boc protecting group of 5m or 5n under acidic conditions such as anhydrous HCl in 1,4-dioxane or TFA in DCM affords R 7 or R 8 is fluorine and L is O, S or NR 3 The corresponding compounds 5a-5b of formula I are obtained, which are either

[0069] Similarly, R 7 or R 8 is chlorine and L is O, S or NR 3Compounds of formula I, 5a and 5b, either of which are: can be prepared in an analogous manner by omitting the KF or CsF fluorination step. [ka]

[0070] Scheme 6 shows the structure of a cyclic aryl group in which L is O, S or NR 3An alternative synthesis of pyrido[3,2-d]pyrimidines 6a-6c of formula I is shown, which are either: 1) dibromo- or dichloropyridine derivative 6d is reacted with (1Z)-N-[(methylsulfonyl)oxy]-ethanimidyl chloride (6e; CAS#1228558-17-5) according to the general procedure described by P.S. Fier (J. Am. Chem. Soc. 2017, 139(28), 9499-9736) to give 3,5-dihalo-4-fluoropicolinonitrile (6f). Alternatively, compound 6f can be prepared by oxidation of 6d with H2O2-urea complex in the presence of trifluoroacetic anhydride, followed by treatment of the corresponding N-oxide with trimethylsilyl cyanide in the presence of dimethylcarbamoyl chloride in a solvent such as dichloromethane. Regioselective Suzuki coupling of 6f with boronic acid 1p, as generally described in WO2021117767A1, gives product 6g. Subsequent reaction of 6g with 2,4-dimethoxybenzylamine (6h) in the presence of Hunig's base with heating in a suitable solvent such as 1,4-dioxane, according to the procedure described in WO2021041671A1, gives compound 6i. Alternatively, 6i can be prepared by a Buchwald-Hartwig amination procedure of 6g with 6h under standard conditions. Pinner reaction of 6i in methanol in the presence of HCl at -78°C to 0°C, followed by hydrolysis of the intermediate iminoester in the presence of saturated aqueous NaHCO3, gives compound 6j. Reaction of 6j with trichloroacetyl isocyanate at 0°C, followed by treatment with anhydrous ammonia in methanol and warming to room temperature, gives compound 6k. Reaction of 6k with POCl3 in the presence of Hunig's base at elevated temperature gives the corresponding 2,4-dichloro-8-fluoropyrido[3,2-d]pyrimidine derivative 6l. Reaction of compound 6l with 1h in the presence of Hunig's base in a solvent such as acetonitrile gives 6m.Treatment of 1i-1k with a suitable base such as potassium fluoride, Hunig's base, K2CO3 or Cs2CO3 / DABCO mixture either neat 1i-1k or in a suitable aprotic solvent followed by reaction with 6m at elevated temperature gives compounds 6n-6p, respectively. Alternatively, 1i-1k and 6m can be coupled with Pd(OAc)2 in the presence of BINAP and Cs2CO3 in toluene at elevated temperature to give 6n-6p, respectively. Removal of the Boc protecting group in 6n-6p under acidic conditions such as anhydrous HCl in 1,4-dioxane or TFA in DCM allows L to be O, S or NR. 3 Compounds 6a to 6c, which are any one of the following, are obtained. [ka]

[0071] Scheme 7 shows a compound in which L is O, S or NR 3Another alternative synthesis of pyrido[3,2-d]pyrimidines 7a-7c of formula I is shown, which are either: Nitration of the picolinic acid derivative 7d with nitric acid in concentrated sulfuric acid gives the corresponding nitro compound 7e. Esterification of 7e with catalytic sulfuric acid in methanol at reflux gives the methyl ester 7f. Reduction of the nitro group of 7f with stannous chloride dihydrate in the presence of hydrochloric acid in an alcohol such as ethanol gives the corresponding amino derivative 7g. Hydrolysis of the ester moiety of 7g in the presence of LiBr and triethylamine in a wet solvent such as acetonitrile or THF containing 6% water (v / v) gives the carboxylic acid 7h (S. Karlsson et al, Tet. Lett. 2007 48, 2497-2499). Treatment of 7h with HATU and ammonium chloride in the presence of sodium bicarbonate in a polar aprotic solvent such as DMF gives the corresponding carboxamide derivative 7i. Reaction of 7i with triphosgene (bis(trichloromethyl)carbonate) in an aprotic solvent such as 1,4-dioxane at 5 °C followed by heating at 110 °C gives the 7-bromopyrido[3,2-d]pyrimidine-2,4(1H,3H)-dione derivative 7j. Reaction of 7j with phosphorus oxychloride in the presence of Hunig's base at 120 °C gives the corresponding dichloro derivative 7k. Reaction of 7k with 1h in the presence of Hunig's base in a solvent such as acetonitrile gives 7l. Treatment of 1i-1k with a suitable base such as sodium hydride, Hunig's base, K2CO3 or Cs2CO3 / DABCO mixture followed by reaction with 7l at elevated temperature gives compounds 7m-7o, respectively. Alternatively, 1i-1k and 7l can be coupled with Pd(OAc)2 in the presence of BINAP and Cs2CO3 in toluene at elevated temperature to generate 7m-7o. Standard Suzuki coupling procedures of 7m-7o with 1p can be used to prepare compounds 7p-7r. Removal of the Boc protecting group in 7p-7r under acidic conditions such as anhydrous HCl in 1,4-dioxane allows L to be converted to O, S or NR 3 This affords pyrido[3,2-d]pyrimidines 7a-7c of Formula I, which are either [ka]

[0072] Abbreviations and Acronyms The following abbreviations and acronyms may be used herein: anhyd.=anhydrous; aq. = aqueous; B2pin2=bis(pinacolato)diboron; Boc = tert-butoxycarbonyl; n-Bu3P = tri-n-butylphosphine; Compd=Compound; d=day; DCM = dichloromethane; DIEA = DIPEA = N,N-Diisopropylethylamine = Hunig's base DMF = N,N-dimethylformamide; DMSO = dimethyl sulfoxide; DMA = N,N-dimethylacetamide; dppf = 1,1'-bis(diphenylphosphino)ferrocene); DTBPF = 1,1'-bis(di-tert-butylphosphino)ferrocene; EtOAc = ethyl acetate; equiv=equivalent; Ex = example; h=time; KOAc = potassium acetate; LiHMDS = lithium bis(trimethylsilyl)amide [LiN(SiMe3)2]; MeOH = methanol; NMP = N-methyl-2-pyrrolidone; min=minutes; Pd(dppf)Cl2 = [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II); RT=room temperature; satd.=saturated solution; TEA = triethylamine; TFA = trifluoroacetic acid; THF = tetrahydrofuran;

[0073] Working Example While the concepts of the present invention have been described in terms of exemplary principles and embodiments, those skilled in the art will recognize that changes can be made to, and equivalents substituted for, what has been described without departing from the scope and spirit of the present disclosure, as defined by the following claims. Example 1 4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-chloronaphthalen-1-yl)-2-((tetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[3,2-d]pyrimidine hydrochloride (1:3) (1-aa)

[0074] TIFF2024545416000040.tif4859 Example 1 (1-aa) was prepared as shown in Scheme 8 below. [ka]

[0075] tert-Butyl (1R,5S)-3-(7-bromo-2-chloropyrido[3,2-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (8c) A mixture of 7-bromo-2,4-dichloropyrido[3,2-d]pyrimidine (8a; CAS#1215074-41-1; 500 mg, 1.80 mmol) and tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (8b; CAS#149771-44-8; 420 mg, 1.98 mmol) in anhydrous 1,4-dioxane (5 mL) was slowly treated dropwise with diisopropylethylamine (1 mL, 5.40 mmol) and the resulting yellow suspension was stirred at room temperature for 16 h. The reaction mixture was diluted with EtOAc and the insoluble solid was filtered, washed with saturated aqueous NaCl solution (3X), dried (MgSO4), filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (eluted with a gradient of 5% to 25% EtOAc in hexanes) to give 700 mg (85%) of tert-butyl (1R,5S)-3-(7-bromo-2-chloropyrido[3,2-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (8c) as a white solid: HPLC-MS (ES + ) m / z MH + =454.

[0076] tert-Butyl (1R,5S)-3-(7-bromo-2-((tetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[3,2-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (8e) A mixture of tert-butyl (1R,5S)-3-(7-bromo-2-chloropyrido[3,2-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (8c; 400 mg, 0.883 mmol) and (tetrahydro-1H-pyrrolidin-7a(5H)-yl)methanol (8d; CAS#78449-72-6; 1 mL, 7.06 mmol) was treated with K2CO3 (365 mg, 2.65 mmol), oven-dried with 4 Å molecular sieves (440 mg) in 1,4-dioxane (3 mL), and heated at reflux with stirring for 16 h. The reaction mixture was cooled to room temperature, diluted with EtOAc, washed with saturated aqueous NaCl solution (3X), dried (MgSO4), filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography eluting with a gradient of 1% to 10% MeOH in DCM to give 232 mg (47%) of tert-butyl (1R,5S)-3-(7-bromo-2-((tetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[3,2-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (8e) as a pale yellow solid: HPLC-MS (ES + ) m / z MH + =559.

[0077] tert-Butyl (1R,5S)-3-(7-(8-chloronaphthalen-1-yl)-2-((tetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[3,2-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (8g) A mixture of tert-butyl (1R,5S)-3-(7-bromo-2-((tetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[3,2-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (8e; 410 mg, 0.734 mmol), 2-(8-chloronaphthalen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (8f; 423 mg, 1.47 mmol), KCO (405 mg, 2.94 mmol) in 1,4-dioxane (4 mL) and water (1.40 mL) was degassed by sparging with N for 45 min. Tetrakis(triphenylphosphine)palladium(0) (127 mg, 0.110 mmol) was added and the reaction mixture was degassed by sparging with N2 for an additional 15 min. The reaction mixture was then heated at 85° C. with stirring under an N2 atmosphere for 16 h, cooled to room temperature, and degassed by sparging with N2 for an additional 15 min. Additional tetrakis(triphenylphosphine)palladium(0) (65 mg, 0.056 mmol) was added and the reaction mixture was degassed by sparging with N2 for an additional 15 min. The reaction mixture was heated at 95° C. with stirring under an N2 atmosphere for 96 h, cooled to room temperature, diluted with EtOAc, washed with saturated aqueous NaCl solution (3x), dried (MgSO4), filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography eluting with a gradient of 0% to 15% MeOH in DCM to give 130 mg (27%) of tert-butyl (1R,5S)-3-(7-(8-chloronaphthalen-1-yl)-2-((tetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[3,2-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (8 g) as a light brown solid: HPLC-MS (ES + ) m / z MH + =641; 1H NMR (300 MHz, DMSO-d6) δ8.54(d, J=2.2 Hz, 1H), 8.10(dd, J=8.1, 12.5 Hz, 2H), 7.82(d, J=2.2 Hz, 1H), 7.72-7.65(m, 2H), 7.60-7.54(m, 2H), 4.29(br s, 2H), 4.01(s, 2H), 2.97-2.90(m, 2H), 2.51-2.49(m, 2H), 2.59-2.53(m, 2H), 2.01-1.65(m, 12H), 1.61-1.50(m, 2H), 1.45(s, 9H).

[0078] 4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-chloronaphthalen-1-yl)-2-((tetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[3,2-d]pyrimidine trihydrochloride (1aa) Under a N2 atmosphere, a solution of tert-butyl (1R,5S)-3-(7-(8-chloronaphthalen-1-yl)-2-((tetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[3,2-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (8g; 124 mg, 0.193 mmol) in DCM (1 mL) was treated with 4 M HCl in 1,4-dioxane (2 mL) and stirred at room temperature for 1.5 h. The reaction mixture was concentrated under reduced pressure, diluted with dichloromethane (1 mL), and concentrated under reduced pressure (repeated three times) to give 104 mg of (4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-chloronaphthalen-1-yl)-2-((tetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[3,2-d]pyrimidine trihydrochloride (1aa) as a light brown solid: HPLC-MS (ES) + ) m / z MH + =541; 1H NMR (300 MHz, DMSO-d6) δ10.9(br s, 1H), 10.0(br s, 1H), 9.71(br s, 1H), 8.70(d, J=2.0 Hz, 1H), 8.21(d, J=7.5 Hz, 1H), 8.13(d, J=7.1 Hz, 1H), 8.03(d, J=2.0 Hz, 1H), 7.75-7.67(m, 2H), 7.63-7.56(m, 2H), 4.63(s, 2H), 4.26(s, 2H), 3.73-3. 65(m, 2H), 3.59-3.44(m, 2H), 3.27-3.15(m, 2H), 2.70(m, 3H), 2.23-1.86(m, 12H).

[0079] Example 2 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-2-((tetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[3,2-d]pyrimidin-7-yl)naphthalen-2-ol (1-ad) [ka] Example 2 (1-ad) was prepared as shown in Scheme 9 below. [ka]

[0080] tert-Butyl (1R,5S)-3-(7-(3-hydroxynaphthalen-1-yl)-2-((tetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[3,2-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (9b) A mixture of tert-butyl (1R,5S)-3-(7-bromo-2-((tetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[3,2-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (8e; 457 mg, 0.819 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-2-ol (42; CAS# 2043962-01-0; 442 mg, 1.64 mmol), KCO (452 ​​mg, 3.28 mmol) in 1,4-dioxane (8 mL) and water (1.60 mL) was degassed by sparging with N for 30 min. Tetrakis(triphenyl-phosphine)palladium(0) (142 mg, 0.123 mmol) was added and the reaction mixture was degassed by sparging with N2 for an additional 20 min. After sparging was complete, the reaction mixture was heated at 85° C. with stirring under a N2 atmosphere for 16 h. The reaction mixture was cooled to room temperature, diluted with EtOAc, washed with saturated aqueous NaCl solution (3X), dried (MgSO4), filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (eluting with a gradient of 0% to 20% i-PrOH containing 1% Et3N (v / v) in DCM) to give 260 mg (51%) of tert-butyl (1R,5S)-3-(7-(3-hydroxynaphthalen-1-yl)-2-((tetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[3,2-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (9b) as a tan solid: HPLC-MS (ES) + ) m / z MH + =623.

[0081] 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-2-((tetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[3,2-d]pyrimidin-7-yl)naphthalen-2-ol (1-ad) The title compound was prepared in a manner similar to that described for Example 1 (1-aa), the crude product was treated with NHOH and purified by silica gel chromatography eluting with a gradient of 0 to 20% MeOH containing 5% NHOH (v / v) to give 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-2-((tetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[3,2-d]pyrimidin-7-yl)naphthalen-2-ol (1-ad) as a tan solid: HPLC-MS (ES + ) m / z MH + =523; 1 H NMR (300 MHz, DMSO-d6) δ10.0(br s, 1H), 8.63(d, J=2.1 Hz, 1H), 7.87(d, J=2.1 Hz, 1H), 7.81(d, J=8.1 Hz, 1H), 7.62(d, J=8.4 Hz, 1H), 7.45(t, J=7.1 Hz, 1H), 7.30 - 7.25(m, 2H), 7.13(d, J=2.4 Hz, 1H), 3.99(s, 2H), 3.54(br s, 2H), 3.35(s, 4H), 2.95 - 2.88(m, 2H), 2.56 - 2.51(m, 2H), 1.92 - 1.50(m,13H).

[0082] Example 3 4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)pyrido[2,3-d]pyrimidine (1-es) TIFF2024545416000044.tif4152 Example 3 (1-es) was prepared as shown in Scheme 10 below. [ka]

[0083] tert-Butyl (1R,5S)-3-(2,7-dichloropyrido[2,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (10b) A solution of tert-butyl (1R,5S)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (8b; 542 mg, 2.55 mmol) in ethyl acetate (10 mL) was added dropwise over 15 min at 0° C. to a stirred solution of 2,4,7-trichloropyrido[2,3-d]pyrimidine (10a; CAS# 938443-20-0; 589 mg, 2.51 mmol) and triethylamine (0.42 mL, 3.01 mmol) in ethyl acetate (50 mL) under N2. After 15 min, the resulting suspension was partitioned between water and further ethyl acetate. The organic extract was washed with saturated NaCl (aq) solution, dried (CaSO4), filtered, and concentrated under reduced pressure. The residue was recrystallized from ethyl acetate / heptane to give 1.02 g of tert-butyl (1R,5S)-3-(2,7-dichloropyrido[2,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (10b) as a pale yellow powder: HPLC-MS (ES + ) m / z MH + =410; 1 H NMR (300 MHz, DMSO-d6) δ8.53(d, J=8.7 Hz, 1H), 7.52(d, J=8.7 Hz, 1H), 4.35(d, J=12.0 Hz, 2H), 4.23(br s, 2H), 3.62(d, J=12.6 Hz, 2H), 1.81-1.78(m, 2H), 1.66-1.62(m, 2H), 1.46(s, 9H).

[0084] tert-Butyl (1R,5S)-3-(2-chloro-7-(8-chloronaphthalen-1-yl)pyrido[2,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (10c) [1,1'-Bis(di-tert-butylphosphino)-ferrocene]dichloropalladium(II) (70 mg, 0.11 mmol) was added to a stirred, degassed yellow suspension of tert-butyl (1R,5S)-3-(2,7-dichloropyrido[2,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (10b; 412 mg, 1.0 mmol), 2-(8-chloronaphthalen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (8f; 578 mg, 2.0 mmol), and potassium carbonate (210 mg, 1.5 mmol) in a 50% (v / v) mixture of water in acetonitrile (10 mL). The suspension was sparged with N2 while stirring at room temperature for 15 min. The sparge tube was replaced with a condenser and the mixture was heated at reflux under N2 for 1 h. The cooled reaction mixture was partitioned between saturated NaCl (aq) solution and ethyl acetate. The organic layer was dried (CaSO4), filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 0-40% EtOAc in hexanes. The combined product containing fractions were evaporated and recrystallized from ethyl acetate / heptane to give 172 mg of tert-butyl (1R,5S)-3-(2-chloro-7-(8-chloronaphthalen-1-yl)pyrido[2,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (10c) as a white powder: HPLC-MS (ESR = 0.01, ... + ) m / z MH + =536; 1 H NMR (300 MHz, DMSO-d6) δ8.56 (d, J=8.6 Hz, 1H), 8.19 (d, J=7.9 Hz, 1H), 8.11 (d, J=8.0 Hz, 1H), 7.74-7.65(m, 2H), 7.61-7.56(m, 3H), 4.43-4.40(m, 2H), 3.68(br s, 1H), 3.64(br s, 1H), 1.85-1.83(m, 2H), 1.72-1.69(m, 2H), 1.47(s, 9H).

[0085] tert-Butyl (1R,5S)-3-(7-(8-chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)pyrido[2,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (7e) (S)-(1-Methylpyrrolidin-2-yl)methanol (10d; CAS#34381-71-0; 0.50 mL, 4.2 mmol) and triethylamine (0.1 mL, 0.72 mmol) were added to tert-butyl (1R,5S)-3-(2-chloro-7-(8-chloronaphthalen-1-yl)pyrido[2,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (7c; 72 mg, 0.13 mmol) and the mixture was heated at 65° C. with stirring for 2 days. The cooled reaction mixture was partitioned between saturated NaHCO3 (aq) solution and ethyl acetate. NaCl (aq), dried (CaSO4), filtered and concentrated under reduced pressure to give 125 mg of tert-butyl (1R,5S)-3-(7-(8-chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)pyrido[2,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (10e) as an off-white solid: HPLC-MS (ES + ) m / z MH + =615.

[0086] 4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)pyrido[2,3-d]pyrimidine (1-es) Trifluoroacetic acid (5.0 mL, 65 mmol) was added to a stirring solution of tert-butyl (1R,5S)-3-(7-(8-chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)pyrido[2,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (10e; 125 mg, 0.20 mmol) in anhydrous DCM (20 mL) at room temperature and stirred for 1 h. The reaction mixture was washed with 10% (w / v) NaOH (aq) and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 0-5% methanol (containing 2% NH4OH) in DCM to give 52 mg of 4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)pyrido[2,3-d]pyrimidine (1-es) as a pale yellow solid: HPLC-MS (ES) + ) m / z MH + =515; 1 H NMR (300 MHz, DMSO-d6) δ8.38 (d, J=8.5 Hz, 1H), 8.16 (dd, J=8.3, 1.2 Hz, 1H), 8.09 (dd, J=8.1, 1.3 Hz, 1H), 7.72-7.63(m, 2H), 7.60-7.54(m, 2H), 7.37(d, J=8.4 Hz, 1H), 4.35-4.22(m, 2H), 4.20-4.00(m, 2H), 3.62-3.51(m, 5H), 2.99-2.93(m, 1H), 2.64- 2.55(m, 1H), 2.36(s, 3H), 2.24-2.15(m, 1H), 2.01-1.90(m, 1H), 1.70-1.64(m, 5H), 1.23(br s, 2H).

[0087] Example 4 4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-chloronaphthalen-1-yl)-2-((tetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[2,3-d]pyrimidine (1-ab) [ka] Example 4 (1-ab) was prepared as shown in Scheme 11 below. [ka]

[0088] tert-Butyl (1R,5S)-3-(7-(8-chloronaphthalen-1-yl)-2-((tetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[2,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (11a) Cesium carbonate (167 mg, 0.52 mmol) was added to a stirred solution of tert-butyl (1R,5S)-3-(2-chloro-7-(8-chloronaphthalen-1-yl)pyrido[2,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (10c; 138 mg, 0.26 mmol) and (tetrahydro-1H-pyrrolidin-7a(5H)-yl)methanol (8d; 110 mg, 0.78 mmol) in anhydrous acetonitrile (5.2 mL) and heated at reflux under N2 for 3 days. The cooled reaction mixture was partitioned between saturated NaCl(aq) solution and ethyl acetate, and the organic extract was dried (CaSO4), filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 1–5% methanol (containing 2% NH4OH) in DCM to give 48 mg of tert-butyl (1R,5S)-3-(7-(8-chloronaphthalen-1-yl)-2-((tetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[2,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (11a) as a clear yellow oil: HPLC-MS (ES) 0.0182; 0.0182; 0.0182. + ) m / z MH + =641.

[0089] 4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-chloronaphthalen-1-yl)-2-((tetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[2,3-d]pyrimidine (1-ab) Trifluoroacetic acid (2.0 mL, 26.1 mmol) was added to a solution of tert-butyl (1R,5S)-3-(7-(8-chloronaphthalen-1-yl)-2-((tetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[2,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (11a; 48 mg, 0.07 mmol) in anhydrous DCM (10 mL) stirred under N2 at 0° C. The solution was stirred at 0° C. for 1 h and then allowed to warm slowly to room temperature over 2 h. The reaction mixture was diluted with 10 mL of DCM, extracted with 5% (w / v) NaOH (aq), dried (CaSO4), filtered and concentrated under reduced pressure to give 38.6 mg of 4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-chloronaphthalen-1-yl)-2-((tetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[2,3-d]pyrimidine (1-ab) as a waxy pale yellow solid: HPLC-MS (ES) + ) m / z MH + =541; 1 H NMR(300 MHz, DMSO-d6)δ8.37(d, 1H, J=8.5Hz), 8.17(dd, 1H, J=8.3, 1.2Hz), 8.09(dd , 1H, J=8.1, 1.3Hz), 7.72-7.63(m, 2H), 7.60-7.54(m, 2H), 7.35(d, 1H, J=8.4 Hz), 4.33-4.31(m, 1H), 4.22-4.19(m, 1H), 4.02(s, 2H), 3.57-3.45(m, 4H), 2.97-2.90(m, 2H), 2.59-2.54(m, 2H), 1.93-1.71(m, 6H), 1.65-1.53(m, 7H). Example 5 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[3,2-d]pyrimidin-7-yl)-5-ethynyl-6-fluoronaphthalen-2-ol (1-bo) [ka] Example 5 (1-bo) was prepared as shown in Scheme 12 below. [ka]

[0090] tert-Butyl (1R,5S)-3-(7-bromo-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[3,2-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (12b) Sodium hydride (66 mg, 1.65 mmol, 60% w / w oil dispersion) was added to a stirred solution of (2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methanol (12a; CAS# 2097518-76-6; 259 mg, 1.65 mmol) in anhydrous THF (11 mL) at 0° C. under N2 atmosphere. After 1 h, tert-butyl (1R,5S)-3-(7-bromo-2-chloropyrido[3,2-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (8c; 500 mg, 1.10 mmol) was added in one portion and the mixture was allowed to warm to room temperature. After 16 h, the mixture was diluted with EtOAc, washed with saturated aqueous NaCl solution (2X), dried (MgSO4), filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography eluting with a gradient of 0–10% MeOH in DCM to give 401 mg (63%) of tert-butyl (1R,5S)-3-(7-bromo-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[3,2-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (12b) as an off-white solid: HPLC-MS (ES + )m / z [M+H + ]=577; 1 H NMR (300 MHz, CDCl3) δ8.49(d, J=2.2 Hz, 1H), 8.05(d, J=2.2 Hz, 1H), 5.27(d, J=53.3 Hz, 1H), 4.35(br s, 2H), 4.17(d, J=10.2 Hz, 1H), 4.04(d, J=10.1 Hz, 1H), 3.41(br s, 1H), 3.25(s, 2H), 3.18-2.90(m, 2H), 2.37-2.06(m, 4H), 2.00-1.64(m, 9H), 1.50(s, 9H).

[0091] tert-Butyl (1R,5S)-3-(7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)-naphthalen-1-yl)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-pyrido[3,2-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (12d) tert-Butyl (1R,5S)-3-(7-bromo-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-pyrido[3,2-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (12b; 300 mg, 0.521 mmol), ((2-fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl)ethynyl)triisopropylsilane (12c; CAS# 2621932-37-2; 293 mg, 0.573 mmol) and K2CO3 (294 mg, 2.14 mmol) were dissolved in dioxane (6.5 mL) and water (1 The mixture was mixed with 1 mL of ethyl acetate and degassed by sparging with N2 with stirring for 20 min. Tetrakis(triphenyl-phosphine)palladium(0) (60 mg, 0.052 mmol) was added and the reaction mixture was degassed by sparging with N2 with stirring for an additional 20 min. The reaction mixture was heated at 80° C. with stirring under an atmosphere of N2 for 16 h, cooled to room temperature, diluted with EtOAc and filtered through Celite. The filtrate was washed with saturated aqueous NaCl solution (3X), dried (MgSO4), filtered and concentrated under reduced pressure. The crude product, a mixture of 12e and 12f, was purified by silica gel column chromatography (eluting with a gradient of 10–50% acetone in DCM) to give 143 mg (31%) of tert-butyl (1R,5S)-3-(7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[3,2-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (12d) as a mixture of atropisomers as a yellow solid (HPLC-MS (ES) 143-38). + )m / z [M+H + ]=883) and 136 mg (36%) of 12e was obtained as an orange-brown solid (HPLC-MS (ES + )m / z [M+H + ]=727).

[0092] 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[3,2-d]pyrimidin-7-yl)-6-fluoro-5-((triisopropylsilyl)-ethynyl)naphthalen-2-ol (12f) At 0 °C, a solution of tert-butyl (1R,5S)-3-(7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[3,2-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (12d; 133 mg, 0.15 mmol) in anhydrous CH3CN (3 mL) was treated with 4 M HCl in dioxane (1 mL) with stirring under a N2 atmosphere. After 1 h, the reaction mixture was absorbed onto Celite and purified by silica gel column chromatography eluting with a gradient of 2–12% MeOH in DCM containing 10% NH4OH (v / v) to give 75 mg (68%) of 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[3,2-d]pyrimidin-7-yl)-6-fluoro-5-((triisopropylsilyl)ethynyl)naphthalen-2-ol (12f) as a pale yellow solid: HPLC-MS (ES) + )m / z [M+H + ]=739; 1H NMR (300 MHz, DMSO-d6)d 10.0(br s, 1H), 8.54(br d, J=2.1 Hz, 1H), 7.97(dd, J=6.0, 9.2 Hz, 1H), 7.76(br t, J=1.9 Hz, 1H), 7.47(t, J=8.9 Hz, 1H), 7.35(d, J=2.4 Hz, 1H), 7.05(br d, J=2.3 Hz, 1H), 5.28(d, J=53.9 Hz, 1H), 4.06(dd, J=4.7, 10.6 Hz, 1H), 3.92(d, J=10.4 Hz, 1H), 3.54(br s, 2H), 3.20-3.05(m, 4H), 3.00(br s, 2H), 2.90-2.75(m, 2H), 2.19-1.56(m, 10H), 0.82(d, J=7.4 Hz, 9H), 0.78(d, J=7.4 Hz, 9H), 0.63-0.44(m, 3H).

[0093] 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[3,2-d]pyrimidin-7-yl)-5-ethynyl-6-fluoronaphthalen-2-ol trihydrochloride(1-bo) Tetrabutylammonium fluoride (in THF, 0.1 mL, 0.11 mmol, 1 M) was added to a solution of 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[3,2-d]pyrimidin-7-yl)-6-fluoro-5-((triisopropylsilyl)ethynyl)naphthalen-2-ol (12f; 65 mg, 0.088 mmol) in anhydrous THF (2.0 mL) at room temperature under N2 atmosphere with stirring. After 1 h, the reaction mixture was diluted with EtOAc and washed successively with HO (2X) and saturated aqueous NaCl solution (2X). The EtOAc layer was dried (MgSO4), filtered, and concentrated under reduced pressure. The aqueous layer was concentrated to dryness under reduced pressure and triturated with DCM, and the resulting DCM extracts were combined, dried (MgSO4), filtered, and concentrated under reduced pressure. A solution of the crude residue in MeOH was treated with 3 M HCl in MeOH (0.2 mL, 0.598 mmol) under a N2 atmosphere at 0° C. Diethyl ether was added slowly until a solid precipitated, and the mixture was stirred at room temperature for 3 days. The resulting solid precipitate was isolated by filtration under a N2 atmosphere, washed with Et2O, and dried under vacuum to give 13 mg (25%) of 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[3,2-d]pyrimidin-7-yl)-5-ethynyl-6-fluoronaphthalen-2-ol trihydrochloride (1-bo) as a brown solid: HPLC-MS (ES) + )m / z [M+H + ]=583; 1H NMR (300 MHz, DMSO-d6)d 11.2(br s, 1H), 10.3(br s, 1H), 9.80(br s, 1H), 9.43(br s, 1H), 8.64(br d, J=1.9 Hz, 1H), 7.99(dd, J=6.2, 9.3 Hz, 1H), 7.91(br t, J=1.6 Hz, 1H), 7.48(t, J=9.0 Hz, 1H), 7.40(br d, J=2.4 Hz, 1H), 7.14(br d, J=2.2 Hz, 1H), 5.58(d, J=52.8 Hz, 1H), 4.62(br s, 2H), 4.25(br s, 2H), 4.10(br s, 1H), 3.87(br s, 1H), 3.82-3.66(m, 4H), 3.22-3.09(m, 2H), 2.77-2.50(m, 2H), 2.38-1.79(m, 10H).

[0094] Nucleotide exchange assay The biological activity of the present examples was measured in a KRAS G12D / SOS1 nucleotide exchange assay performed by Reaction Biology Corporation (RBC), 1 Great Valley Parkway, Suite 2 Malvern, PA 19355, USA. This assay evaluates the SOS1-mediated exchange of Bodipy-GDP for GTP observed with KRAS G12D.

[0095] Compounds and reference standard (MRTX1133) were incubated at 10 concentrations IC with 3-fold serial dilutions at a starting concentration of 10 μM. 50 The compound pre-incubation time was 30 minutes at room temperature and curve fitting was performed if the activity at the highest compound concentration was less than 65%. Reaction buffer: 40mM HEPES 7.4, 10mM MgCl2, 1mM DTT 0.002% Triton X100, 0.5% DMSO. Enzyme: SOS1 (RBC cat# MSC-11-502). Recombinant human SOS1 (Genbank accession# NM_033360.3 ; aa 564-1049, expressed in E. Coli with C-terminal StrepII). KRAS G12D: Recombinant human KRAS G12D (aa 2-169, expressed in E. coli with an N-terminal TEV-cleavable his-tag). KRAS is preloaded with a 5-fold excess of Bodipy-GDP. Excess Bodipy-GDP is separated from the loaded protein using spin desalting columns. Final concentrations: KRAS-bodipy-GDP is 0.125 μM; SOS1 is 750 nM; and GTP is 25 μM.

[0096] Reaction Method: 1. Inject 10 μL of freshly prepared 1.5x KRAS solution in reaction buffer into reaction wells. 2. Compounds in 100% DMSO are delivered into the buffer using acoustic technology (Echo550; nanoliter range). 3. Compounds are incubated with KRAS for 30 minutes at room temperature. 4. Prepare a 3x (SOS1+GTP) solution in reaction buffer. 5. Inject 5 μL of SOS1+GTP solution into reaction wells (as a no SOS1 control, inject only GTP into column 1). 6. Monitor the progress of the reaction by the decrease in fluorescent signal using a PHERAstar (BMG Labtech plate reader (Ex / Em=485 / 520)) for 30 minutes at room temperature.

[0097] Data analysis: Fluorescence data were normalized using the following formula and fitted to a "one-phase exponential decay" equation using GraphPad prism software. The plateau was fixed to zero (used for non-covalent inhibitors) and the percentage x 1000 was calculated as the IC 50 was used to calculate the value.

number

[0098] Background subtracted signals (wells without SOS1 protein were used as background) were converted to activity (%) relative to DMSO control. Data were analyzed using GraphPad Prism 4 with "sigmoidal dose response (variable slope)"; 4 parameters with Hill slope. Constraints were lower limit (constant equal to 0) and upper limit (must be less than 120). [Table 1] * Reversible inhibitors were analyzed using the rate constant method (plateau = 0) with Bodipy-GDP / KRAS G12D as substrate and 0.5% DMSO added to the reaction mixture. MRTX1133 is the KRAS G12D reference standard, see Wang et al in J. Med. Chem. 2022, 65 (4), 3123-3133.

[0099] KRAS G12D cell assay KRAS G12D cellular activity of Example 5 (compound 1-bo) and the reference standard MRTX1133 was measured using a target engagement cellular assay (NanoBRET) in transiently transfected HEK293 cells by Reaction Biology Corporation (RBC), 1 Great Valley Parkway, Suite 2 Malvern, PA 19355, USA. TM) were measured. HEK293 cells were cultured to 70-80% confluence prior to the assay, and then trypsinized to harvest the cells. MRTX1133 was used as a KRAS G12D reference compound. Each test compound solution was transferred from the compound source plate to the wells of a 384-well white non-binding surface plate using an Echo 550 prior to the assay.

[0100] A 10 μg / mL solution of DNA in serum-free Opti-MEM was prepared consisting of 1 μg of KRAS 2B(G12D) large bit vector and 1 μg of KRAS 2B(G12D) small bit vector, and 8 μg of transfection carrier DNA. This mixture was then treated with 30 μL of FuGENE HD Transfection Reagent per milliliter of DNA mixture to form lipid:DNA complexes. The resulting mixture was mixed by gentle inversion and incubated at ambient temperature for 20 minutes to allow complex formation. A mixture of 1 part lipid:DNA complex and 20 parts suspended HEK293 cells was added to a sterile conical tube and mixed by gentle inversion. The mixture of cells + lipid:DNA complexes was then added to a sterile tissue culture dish and incubated for 24 hours. The medium was removed from the dish by aspiration, followed by trypsinization to release the cells from the tissue culture dish. The trypsin was then neutralized with serum-containing medium and the cells were pelleted in the conical tube by centrifugation at 200 × g for 5 min. The cell density was 2 × 10 in Opti-MEM without phenol red. 5 Complete 20X NanoBRET TM One part of RAS Tracer Reagent was dispensed into 20 parts of cells in the conical tube and gently inverted to mix. The resulting cell suspension was dispensed into a white 384-well NBS plate containing test compounds (10 3-fold dilutions starting at 10 μM) and placed at 37° C., 5% CO2 for 2 hours. The final concentration of RAS tracer K2 was 1 μM. The NBS plate was removed from the incubator and allowed to equilibrate to room temperature for 15 minutes.

[0101] Freshly prepared substrate solution (3X) in assay medium was added to each well of a 384-well NBS plate and incubated for 3 minutes at room temperature. The donor emission wavelength (460 nm) and acceptor emission wavelength (600 nm) were measured using an Envision 2104 plate reader. For each sample, the raw BRET ratio was calculated by dividing the acceptor emission value (600 nm) by the donor emission value (460 nm). To correct for background, the BRET ratio in the absence of tracer (average of the no tracer control samples) was subtracted from the BRET ratio of each sample. The BRET ratio was calculated using the following formula: BRET ratio = [(acceptor sample ÷ donor sample) - (acceptor no tracer control ÷ donor no tracer control)]. The normalized BRET response (%) was calculated using the following formula: (BRET ratio of test compound / BRET ratio of DMSO control) * 100%. IC 50 Plot the curves and calculate IC in GraphPad Prism 4 based on a sigmoidal dose-response equation. 50 The value was calculated. [Table 2] * NanoBRET TM Target Engagement Cellular Assay (KRAS G12D). MRTX1133 is the KRAS G12D reference standard, see Wang et al in J. Med. Chem. 2022, 65 (4), 3123-3133.

Claims

1. Formula I: [Formula 1] [During the ceremony, A is hydrogen, halogen, hydroxy, -C 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl, -C 0-3 Alkyl(C 3-6 Cycloalkyl), -C 1-6 Alkyl(halo), -C 1-6 Alkyl (OH), -O(C 1-4 alkyl), -C 1-3 Alkyl(C 1-4 Alkoxy), -CN, -CO 2 R 3 , -CO 2 N(R 3 ) 2 , -NO 2 , -N(R 3 ) 2 , -P(O)(R 4 ) 2 , -SR 3 , -S(O)R 3 , -SO 2 R 3 or aryl or heteroaryl optionally substituted with one or more 5- to 6-membered heterocyclic rings; W is CR 5 or N, provided that if W is N, then Y is CR 5 and X is CR 5 or N, provided that if X is N, then Y is CR 5 and W is N; Y is CR 5 or N, with the proviso that if Y is N, then X and W are both CR 5 and L is a bond, O, S, or NR 3 and n is 0 to 2; Z is C 3-7C(R) is selected from cycloalkyl, a saturated or partially unsaturated 4- to 7-membered nitrogen-containing ring, and a saturated or partially unsaturated 7- to 10-membered nitrogen-containing bridged bicyclic ring. 3 ) 2 or a cyclic compound; R 1 is hydrogen, hydroxy, halogen, -C 1-3 Alkyl, -C 1-3 Alkyl(OH), -C 1-3 Alkyl(halo), -C 1-3 Alkyl(C 1-3 Alkoxy), -C 1-3 Alkyl (CN) or -C 1-3 Alkyl (P(O)R 3 2 ) selected from; R 2 is hydrogen, halogen, hydroxy, -C 1-4 Alkyl, -C 2-4 Alkenyl, -C 2-4 Alkynyl, -C 0-3 Alkyl(C 3-6 Cycloalkyl), -C 1-4 Alkyl(halo), -C 1-4 Alkyl (OH), -O(C 1-4 alkyl), -C 1-3 Alkyl(C 1-3 Alkoxy), -CN, -CO 2 R 3 , -CO 2 N(R 3 ) 2 , -NO 2 , -N(R 3 ) 2 , -PO(R 4 ) 2 , -SR 3 , -S(O)R 3 , -SO 2 R 3 , or -(C 0-3 Alkyl)R 6 Selected from: Each R 3 are the same or different, hydrogen, C 1-4 selected from alkyl, aryl, or heteroaryl; Each R 4are the same or different and can be hydrogen, hydroxyl, C 1-4 Alkyl, aryl, heteroaryl, C 1-4 selected from alkoxy, aryloxy, or heteroaryloxy; Each R 5 may be the same or different, and are hydrogen, halogen, C 1-4 Alkyl, C 1-4 Perdeuteroalkyl, -(C 0-2 Alkyl)alkenyl, -(C 0-2 alkyl)alkynyl, -(C 0-2 alkyl)cycloalkyl, -C 1-4 Haloalkyl, -O(C 1-4 alkyl), -S(C 1-4 alkyl), -(C 0-2 alkyl)cyano, -O(C 1-4 haloalkyl) or -S(C 1-4 haloalkyl); R 6 is N(R 3 ) 2 or a 4- to 7-membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group N, O, and S. or a pharma- ceutically acceptable salt, solvate, or prodrug thereof.

2. The compound of claim 1, wherein the compound of formula I is selected from compounds 1-aa to 1-gd and 2-aa to 2-gc, and pharma- ceutically acceptable salts, solvates, or prodrugs thereof: [chemical 2] [C3] [C4] [C5] [C6] [C7] [C8] [C9] [C10] [C11] [C12] [C13] [C14] [C15] [C16] [C17] [C18] [C19] [C20] [C21] [C22] [C23] [C24] [C25] [C26] [C27] [C28] [C29]

3. A pharmaceutical composition comprising at least one compound according to any one of claims 1 to 2, or a salt, solvate or prodrug thereof, together with a pharma- ceutically acceptable carrier.

4. 4. A method of treating a disease, disorder, or medical condition in a patient, comprising providing to the patient in need of treatment a therapeutic agent comprising at least one compound according to any one of claims 1 to 3 or a salt, solvate, or prodrug thereof.

5. 5. The method of treating a disease, disorder, or medical condition according to claim 4, wherein the disease, disorder, or medical condition comprises various cancers.

6. 6. The method of treating a disease, disorder, or medical condition according to claim 5, wherein the disease, disorder, or medical condition is mediated by KRAS.

7. 7. The method of treating a disease, disorder, or medical condition according to claim 6, wherein the disease, disorder, or medical condition is mediated by KRAS mutant G12D.

8. 6. The method of treating the disease, disorder, or medical condition of claim 5, wherein the cancer is selected from glioma (glioblastoma), acute myelogenous leukemia, acute myeloid leukemia, myelodysplastic / myeloproliferative neoplasms, sarcoma, chronic myelomonocytic leukemia, non-Hodgkin's lymphoma, astrocytoma, melanoma, non-small cell lung cancer, small cell lung cancer, cholangiocarcinoma, chondrosarcoma, colon cancer, colorectal cancer, rectal cancer, pancreatic cancer, and combinations thereof.

9. The method of any one of claims 4 to 8, further comprising administering to a patient in need of treatment at least one additional therapeutic agent.

10. 10. The method of claim 9, wherein the additional therapeutic agent is selected from doxorubicin, paclitaxel, docetaxel, cisplatin, camptothecin, temozolomide, avastin, herceptin, erbitux, EGFR inhibitors, osimertinib, rezivertinib, CDK4 / 6 inhibitors, abemaciclib, palbociclib, ribociclib, c-MET inhibitors, capmatinib, volitinib, ALK inhibitors, crizotinib, alectinib, ceritinib, brigatinib, entrectinib, lorlatinib, PD-1 antagonists, PD-L1 antagonists, ipilimumab, embrolizumab, nivolumab, and combinations thereof.

11. 3. The compound of claim 2, wherein the compound of formula I is selected from at least one of the compounds of formula 1-ap, 1-bo, 1-ca, 1-dk, 1-ei, 1-gb, 2-ab, 2-af, 2-ba, 2-be, 2-ca, 2-ce, 2-da, 2-de, 2-ea, 2-ee, and 2-fa, or a salt, solvate, or prodrug thereof. [C30] [C31]

12. 4. The pharmaceutical composition of claim 3, comprising at least one of compounds 1-ap, 1-bo, 1-ca, 1-dk, 1-ei or 1-gb or a salt, solvate or prodrug thereof, together with a pharma- ceutically acceptable carrier.

13. 13. A method of treating the disease, disorder or medical condition of claim 4, comprising providing the pharmaceutical composition of claim 12 to a patient in need of treatment.

14. 14. The method of claim 13, wherein the disease, disorder or medical condition comprises various cancers.

15. 14. The method of treating a disease, disorder, or medical condition of claim 13, wherein the disease, disorder, or medical condition is mediated by KRAS.

16. 16. The method of treating a disease, disorder, or medical condition according to claim 15, wherein the disease, disorder, or medical condition is mediated by KRAS mutant G12D.

17. 15. The method of treating the disease, disorder, or medical condition of claim 14, wherein the cancer is selected from glioma (glioblastoma), acute myeloid leukemia, acute myelogenous leukemia, myelodysplastic / myeloproliferative neoplasms, sarcoma, chronic myelomonocytic leukemia, non-Hodgkin's lymphoma, astrocytoma, melanoma, non-small cell lung cancer, small cell lung cancer, cholangiocarcinoma, chondrosarcoma, colon cancer, colorectal cancer, rectal cancer, pancreatic cancer, and combinations thereof.

18. A method of treating KRAS G12D-associated cancer, comprising administering to a patient in need of treatment a therapeutic agent comprising at least one compound according to any one of claims 1 to 3 or a salt, solvate or prodrug thereof.

19. 20. The method of treating a KRAS G12D associated cancer of claim 18, wherein the cancer is selected from glioma (glioblastoma), acute myeloid leukemia, acute myelogenous leukemia, myelodysplastic / myeloproliferative neoplasms, sarcoma, chronic myelomonocytic leukemia, non-Hodgkin's lymphoma, astrocytoma, melanoma, non-small cell lung cancer, small cell lung cancer, cholangiocarcinoma, chondrosarcoma, colon cancer, colorectal cancer, rectal cancer, pancreatic cancer, and combinations thereof.

20. The method of any one of claims 18 to 19, further comprising administering to a patient in need of treatment at least one additional therapeutic agent.

21. 21. The method of claim 20, wherein the additional therapeutic agent is selected from doxorubicin, paclitaxel, docetaxel, cisplatin, camptothecin, temozolomide, avastin, herceptin, erbitux, EGFR inhibitors, osimertinib, resibertinib, CDK4 / 6 inhibitors, abemaciclib, palbociclib, ribociclib, c-MET inhibitors, capmatinib, voritinib, ALK inhibitors, crizotinib, alectinib, ceritinib, brigatinib, entrectinib, lorlatinib, PD-1 antagonists, PD-L1 antagonists, ipilimumab, embrolizumab, nivolumab, and combinations thereof.